77
Participants
Start Date
March 6, 2017
Primary Completion Date
February 28, 2020
Study Completion Date
February 28, 2020
Lanreotide (Autogel formulation)
120mg every 28 days until disease progression, death, or unacceptable toxicity
Placebo
Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
Best Supportive Care
Best Supportive Care is best available therapy at the choice of the investigator
AKH und Med. University Vienna Allg Krankenhaus Wien, Vienna
NET-Centre, Rigshospitalet, Copenhagen
Klinikum Wels-Grieskirchen GmbH, Wels
Aarhus University Hospital, Aarhus
Hospital Universitari, Vall d'Hebron, Barcelona
Memorial Sloan Kettering Cancer Center, New York
Evangelische Lungenklinik Berlin, Berlin
CLLC, Institut Paoli Calmettes, Marseille
Roswell Park Cancer Center, Buffalo
Universita di Genova, Genova
University of Pennsylvania, Philadelphia
Insittuto Clinico Humanitas, Rozzano
University Hospital Ramón y Cajal, Madrid
Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier
CHU de Rennes - Hôpital Pontchaillou, Rennes
Hospital Universitario Marqués de Valdecilla, Santander
Centre René Gauducheau ICO institut de Cancerologie de l'Ouest, Saint-Herblain
Universitätsklinikum Essen (AöR), Essen
University of Cincinnati, Cincinnati
Insituti Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST), Meldola
Karmanos Cancer Center, Detroit
Hospital Universitario Miguel Servet, Zaragoza
Mayo Clinic, Rochester
Centre Oscar Lambret, Lille
Johann Wolfgang Goethe-Universitätsklinikum Frankfurt, Frankfurt
Hôpital Edouard Herriot, Lyon
Ochsner Medical Center, New Orleans
Texas Oncology, Dallas
Texas Oncology-Forth Worth, Fort Worth
Azienda Ospedaliera Antonio Cardarelli, Napoli
Rocky Mountain Cancer Center, Denver
Arizona Oncology Associates, Tucson
VA Greater Los Angeles, Los Angeles
Institut Gustave Roussy, Villejuif
Oregon Health and Science Center, Portland
Zentralklinik Bad Berka GmbH, Bad Berka
Dana-Farber Institute, Boston
Tom Baker Cancer Center, Calgary
QEII Health Sciences Centre, Halifax
Sunnybrook Health Sciences Centre, Toronto
McGill University Health Center, Montreal
Saskatoon Cancer Centre, Saskatoon
Cancer Care of Manitoba, Winnipeg
Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia, Perugia
Antoni van Leeuwenhoek, Amsterdam
Maastricht University Medical Center, Maastricht
Zakladu Medycyny Nuklearne i Endokrynologii Onkologicznej, Gliwice
University Center of Ophtalmology & Oncology, Katowice
Szpital Uniwersytecki W, Krakow
Szpital Kliniczny im. H. Święcickiego U.M., Poznan
GAMMED, Warsaw
Cancer Center, Beatson Oncology, Glasgow
Royal Surrey County Hospital, Guildford
Royal Free Hospital, London
King's College Hospital, London
Christie Hospital, Manchester
Churchill Hospital, Oxford
Lead Sponsor
Ipsen
INDUSTRY